Congenital PAI-1 deficiency results in psoas hematoma in an Indian patient
Bleeding due to inherited defects in fibrinolytic cascade genes is rare. Fibrinolysis is an in-built regulatory mechanism responsible for plasmin-mediated dissolution of fibrin clots due to interplay between activators and inhibitors of fibrinolysis. Thus, deficiency of the inhibitors of fibrinolysis, either alpha-2 antiplasmin ( α2-AP) or plasminogen activator inhibitor- 1 (PAI-1) results in hyperfibrinolysis leading to premature fibrin clot lysis and associated hemorrhagic diathesis. Prevalence of congenital disorders of fibrinolysis is unknown. (Source: Thrombosis Research)
Source: Thrombosis Research - April 3, 2020 Category: Hematology Authors: Aniket Prabhudesai, Ratna Sharma, Shrimati Shetty, Ashish Phadnis, Bipin Kulkarni Tags: Letter to the Editors-in-Chief Source Type: research

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale
We recently proposed a scale for assessment of patient-relevant functional limitations following an episode of venous thromboembolism (VTE). Further development of this post-VTE functional status (PVFS) scale is still needed. (Source: Thrombosis Research)
Source: Thrombosis Research - March 30, 2020 Category: Hematology Authors: G.J.A.M. Boon, S. Barco, L. Bertoletti, W. Ghanima, M.V. Huisman, S.R. Kahn, S. Noble, P. Prandoni, R.P. Rosovsky, A.K. Sista, Bob Siegerink, F.A. Klok Tags: Full Length Article Source Type: research

Variable D-dimer thresholds in predicting peripherally inserted central catheter-related vein thrombosis in patients with hematological malignancies: A pilot study
Patients with hematological malignancies and peripherally inserted central venous catheters (PICCs) tend to develop catheter-associated upper extremity venous thromboses (UEVTs) and pulmonary emboli (PE) [1,2]. Active cancer, malposition and PICC gauge are common risk factors for PICC-UEVTs [2,3]. The association between D-dimer thresholds before catheter insertion and the development of PICC-UEVT in cancer patients remains unknown. D-dimers have been widely used in clinical practice as a high-sensitivity diagnostic approach for suspected venous thromboembolisms (VTEs) [4]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 30, 2020 Category: Hematology Authors: Junren Kang, Wenyan Sun, Hailong Li, Enling Ma, Wei Chen Tags: Letter to the Editors-in-Chief Source Type: research

Editorial Board
(Source: Thrombosis Research)
Source: Thrombosis Research - March 27, 2020 Category: Hematology Source Type: research

Venous thromboembolism in patients hospitalized for hip joint replacement surgery
Venous thromboembolism (VTE) is a potentially life-threatening disease. Major transient risk factors include trauma, surgery, and immobilization. Patients undergoing hip joint replacement (HJR) are characterized by a high risk of postoperative VTE, but data on the time trends of VTE rates in this population are sparse. (Source: Thrombosis Research)
Source: Thrombosis Research - March 27, 2020 Category: Hematology Authors: Karsten Keller, Lukas Hobohm, Stefano Barco, Irene Schmidtmann, Thomas M ünzel, Martin Engelhardt, Markus Goldhofer, Stavros V. Konstantinides, Philipp Drees Tags: Full Length Article Source Type: research

Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants
Lupus anticoagulant (LA)-detection is performed by testing plasma with activated partial thromboplastin time (APTT)-derived and dilute-Russell-viper-venom (dRVV)-derived tests. Results are interpreted by comparison to cut-off values determined by testing plasma from healthy-subjects. Several issues are concerned with the determination of LA cut-offs. Among them, the identification/rejection of outliers (i.e., aberrant values) prior statistical analysis is one of the most important and poorly defined. (Source: Thrombosis Research)
Source: Thrombosis Research - March 26, 2020 Category: Hematology Authors: Veena Chantarangkul, Flora Peyvandi, Armando Tripodi, Investigating Group Tags: Full Length Article Source Type: research

TEG in pregnancy: Current challenges and future potential applications
This article deals with a very pe rtinent topic and fills two major research gaps: (1) need for a sufficiently powered study to establish TEG reference intervals and (2) need for separate TEG reference intervals for each trimester of pregnancy. (Source: Thrombosis Research)
Source: Thrombosis Research - March 24, 2020 Category: Hematology Authors: Ariunzaya Amgalan, Maha Othman Tags: Letter to the Editors-in-Chief Source Type: research

Role of thromboelastography in predicting and defining pump thrombosis in left ventricular assist device patients
Optimal anticoagulation for left ventricular assist device recipients aims to balance thrombosis and bleeding complications. Routine plasma-based coagulation tests may not accurately reflect overall hemostasis, and surrogate markers are used to help guide clinicians in the diagnosis of pump thrombosis. Thromboelastography derived coagulation index (CI) has been shown to be a parameter that can reflect “normocoagulability” in mechanical circulatory support device patients, but there is minimal data with regard to outcomes available. (Source: Thrombosis Research)
Source: Thrombosis Research - March 19, 2020 Category: Hematology Authors: Ranran Xia, Sara Varnado, Edward A. Graviss, Duc T. Nguyen, Ana Cruz-Solbes, Ashrith Guha, Jill C. Krisl Tags: Full Length Article Source Type: research

Current imaging modalities for diagnosing cerebral vein thrombosis – A critical review
Cerebral vein thrombosis (CVT) is a rare presentation of venous thromboembolism. Prompt and accurate diagnosis is essential as delayed recognition and treatment may lead to permanent disability or even death. Since no validated diagnostic algorithms exist, the diagnosis of CVT mainly relies on neuroimaging. Digital subtraction angiography (DSA) is the historical diagnostic standard for CVT, but is rarely used nowadays and replaced by computed tomography (CT) and magnetic resonance imaging (MRI). (Source: Thrombosis Research)
Source: Thrombosis Research - March 18, 2020 Category: Hematology Authors: Lisette F. van Dam, Marianne A.A. van Walderveen, Lucia J.M. Kroft, Nyika D. Kruyt, Marieke J.H. Wermer, Matthias J.P. van Osch, Menno V. Huisman, Frederikus A. Klok Tags: Review Article Source Type: research

Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia
This study aimed to characterize the phylogenetic diversity of the fecal microbiota and its relationship with the platelet activation status in patients with ITP. (Source: Thrombosis Research)
Source: Thrombosis Research - March 18, 2020 Category: Hematology Authors: Chanjuan Liu, Luya Cheng, Lili Ji, Feng Li, Yanxia Zhan, Boting Wu, Yang Ke, Pu Chen, Fanli Hua, Ling Yuan, Zhihui Min, Lihua Sun, Hao Chen, Yunfeng Cheng Tags: Full Length Article Source Type: research

Electrocardiographic changes as a prognostic tool for hospitalized patients with pulmonary embolism
Acute pulmonary embolism (PE) may exhibit variable mortality rates, ranging from30% [1]. In terms of short-term prognosis, risk stratification is a critical step in planning the therapeutic strategy for PE [2]. The PE severity index (PESI) and simplified PESI score are the most extensively validated scores for predicting 30-day mortality [3,4]. These scoring systems are useful to identify low-risk patients appropriate for an outpatient setting, but not to predict high-risk patients for advanced therapy [5]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 18, 2020 Category: Hematology Authors: Sun Ha Choi, Seung-Ick Cha, Ji-Eun Park, Sunji Park, Yong-Hoon Lee, Hyewon Seo, Seung-Soo Yoo, Shin-Yup Lee, Jaehee Lee, Chang-Ho Kim, Jae-Yong Park Tags: Letter to the Editors-in-Chief Source Type: research

60  mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study
Ticagrelor is a new novel, reversibly binding, direct-acting P2Y12 receptor antagonist. When compared with clopidogrel, ticagrelor had a more potent and more predictable antiplatelet aggregation effect. Current guidelines recommend that ticagrelor 90  mg twice daily was superior to clopidogrel 75 mg once daily in coronary artery disease (CAD) patients [1]. However, increasing evidence showed ticagrelor increased the risk of bleeding, dyspnea and bradycardia [2–3], indicating that lower doses of ticagrelor could be a good option for patient s with CAD. (Source: Thrombosis Research)
Source: Thrombosis Research - March 18, 2020 Category: Hematology Authors: Meijiao He, Yun Zhang, Wei Yan, Guangzhong Liu, Danghui Sun, Yue Yuan, Jing Shi, Yihui Kong, Yue Li Tags: Letter to the Editors-in-Chief Source Type: research

Progress of the ALIFE2 study: A dynamic road towards more evidence
Investigator-initiated studies are invaluable, especially in fields that are not particularly of interest for the pharmaceutical industry because they are either less profitable or concern special patient groups such as pregnant women. However, designing, conducting, and completing an investigator-initiated randomised controlled trial is challenging. Patients and physicians' preferences, ethics requirements, (international) legislation and funding are all areas where such challenges are encountered. (Source: Thrombosis Research)
Source: Thrombosis Research - March 18, 2020 Category: Hematology Authors: Eva N. Hamuly ák, Paulien G. de Jong, Luuk J.J. Scheres, Lauren J. Ewington, Saskia Middeldorp, Siobhan Quenby, Mariëtte Goddijn Tags: Review Article Source Type: research

Targeting of externalized αB-crystallin on irradiated endothelial cells with pro-thrombotic vascular targeting agents: Potential applications for brain arteriovenous malformations
This study explored αB-crystallin (CRYAB) as a radiation induced target and pre-tested the specificity and efficacy of a CRYAB-targeting coaguligand for in vitro thrombus induction. (Source: Thrombosis Research)
Source: Thrombosis Research - March 17, 2020 Category: Hematology Authors: Sinduja Subramanian, Zhenjun Zhao, Fahimeh Faqihi, Georges E. Grau, Valery Combes, David W. Inglis, Vaughan Moutrie, Marcus A. Stoodley, Lucinda S. McRobb Tags: Full Length Article Source Type: research

Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease
High plasma levels of activated Factor VII-Antithrombin complex (FVIIa-AT) have been associated with an increased risk of cardiovascular mortality in patients with stable coronary artery disease (CAD). (Source: Thrombosis Research)
Source: Thrombosis Research - March 14, 2020 Category: Hematology Authors: Baroni Marcello, Martinelli Nicola, Lunghi Barbara, Marchetti Giovanna, Castagna Annalisa, Stefanoni Filippo, Pinotti Mirko, Woodhams Barry, Olivieri Oliviero, Bernardi Francesco Tags: Full Length Article Source Type: research

Short-term exposure to PM2.5 and risk of venous thromboembolism: A case-crossover study
Short-term exposure to air pollution increases the risk of cardiovascular mortality and morbidity but little evidence is available on pollution effects on venous thromboembolism (VTE), a common vascular disease. (Source: Thrombosis Research)
Source: Thrombosis Research - March 13, 2020 Category: Hematology Authors: Matteo Renzi, Massimo Stafoggia, Paola Michelozzi, Marina Davoli, Francesco Forastiere, Angelo G. Solimini Tags: Full Length Article Source Type: research

A novel splicing mutation in the PROS1 gene causes hereditary protein S deficiency in a Chinese family with thrombotic disease
Protein S (PS) is a vitamin K-dependent plasma glycoprotein that acts as a non-enzymatic cofactor for activated protein C (APC) and inactivates factor Va and VIIa [1]. Hereditary PS deficiency (MIM#612336) is an autosomal dominant haploinsufficiency that is associated with venous thrombosis [2]. PS is encoded by the PROS1 gene, located in 3q11.2, which contains 15 exons and spans more than 101  kilobase pairs (kb) [3]. The detection rates of PROS1 variation in hereditary PS deficiency range from 50% to 90% [4]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 11, 2020 Category: Hematology Authors: Ya Tan, Kai Yang, Jing Wang, Xinping Sun, Ruirui Li, Zhe Dong, Na Zhao, Yousheng Yan, Li Lin Tags: Letter to the Editors-in-Chief Source Type: research

Myocardial functions, blood pressure changes, and arterial stiffness in children with severe hemophilia A
This study investigated the myocardial functions, blood pressure changes, arterial stiffness, and risk factors associated with cardiovascular diseases in children with hemophilia. (Source: Thrombosis Research)
Source: Thrombosis Research - March 10, 2020 Category: Hematology Authors: Zeynep Canan Özdemir, Pelin Köşger, Birsen Uçar, Özcan Bör Tags: Full Length Article Source Type: research

Molecular genetic analysis of inherited protein C deficiency caused by the novel large deletion across two exons of PROC
Protein C (PC) is a vitamin K-dependent serine protease precursor that is mainly synthesized in the liver. PC circulates in the blood as a glycoprotein (62  kDa) consisting of a heavy chain (41 kDa) and a light chain (21 kDa) connected by a disulfide bond. PC is rapidly activated by the thrombin-thrombomodulin complex, becoming activated PC (APC). With protein S (PS) as a cofactor, PC inactivates activated factor V and activated factor VIII [1]. Inherited PC deficiency is, along with antithrombin (AT) deficiency and PS deficiency, a key risk factor for venous thromboembolism (VTE) [2]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 10, 2020 Category: Hematology Authors: Tomoki Togashi, Makiko Meguro-Horike, Satomi Nagaya, Sayaka Sugihara, Tatsuo Ichinohe, Yuhei Araiso, Koichi Yamaguchi, Kotaro Mori, Yuta Imai, Kana Kuzasa, Shin-ichi Horike, Hidesaku Asakura, Atsushi Watanabe, Eriko Morishita Tags: Letter to the Editors-in-Chief Source Type: research

Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study
BAY 81-8973 (Kovaltry ®), a recombinant factor VIII (rFVIII) product, was efficacious and well tolerated in paediatric previously treated patients (PTPs) with severe haemophilia A for ≥50 exposure days (EDs) in the LEOPOLD Kids study. Because long-term prophylaxis (≥100 EDs) can provide substantial patient benefits, FVIII products should demonstrate long-term safety and efficacy. (Source: Thrombosis Research)
Source: Thrombosis Research - March 9, 2020 Category: Hematology Authors: Gili Kenet, Rolf Ljung, Luminita Rusen, Bryce A. Kerlin, Victor Blanchette, Sonata Saulyt ė-Trakymienė, Valentina Uscatescu, Horst Beckmann, Despina Tseneklidou-Stoeter, Nikki Church Tags: Full Length Article Source Type: research

Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19]
The authors regret that panel E of Fig. 1 was missing, showing the cumulative incidence of the primary outcome in hematologic cancer. (Source: Thrombosis Research)
Source: Thrombosis Research - March 6, 2020 Category: Hematology Authors: F.I. Mulder, N. van Es, N. Kraaijpoel, M. Di Nisio, M. Carrier, A. Duggal, M. Gaddh, D. Garcia, M.A. Grosso, A.K. Kakkar, M.F. Mercuri, S. Middeldorp, G. Royle, A. Segers, S. Shivakumar, P. Verhamme, T. Wang, J.I. Weitz, G. Zhang, H.R. B üller, G. Raskob Source Type: research

The gut microbiome and thromboembolism
The gut microbiome plays a critical role in various inflammatory conditions, and its modulation is a potential treatment option for these conditions. The role of the gut microbiome in the pathogenesis of thromboembolism has not been fully elucidated. In this review, we summarize the evidence linking the gut microbiome to the pathogenesis of arterial and venous thrombosis. In a human host, potentially pathogenic bacteria are normal residents of the human gut microbiome, but significantly outnumbered by commensal anaerobic bacteria. (Source: Thrombosis Research)
Source: Thrombosis Research - March 6, 2020 Category: Hematology Authors: Rida Abid Hasan, Andrew Y. Koh, Ayesha Zia Tags: Review Article Source Type: research

Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely
In patients receiving anticoagulation for deep vein thrombosis (DVT), a variety of reasons (including active bleeding or high-risk for bleeding) may lead into premature discontinuation of therapy (prior to completing 90  days). The relative frequency and clinical consequences of premature discontinuation in contemporary patients remain unknown. (Source: Thrombosis Research)
Source: Thrombosis Research - March 5, 2020 Category: Hematology Authors: Jos é A. Nieto, Damian Mora, Behnood Bikdeli, Montserrat Perez Pinar, Reina Valle, José María Pedrajas, Isabelle Mahé, José González-Martínez, María del Carmen Díaz-Pedroche, Manuel Monreal, the RIETE Investigators Tags: Review Article Source Type: research

Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study
Studies using administrative data commonly rely on diagnosis codes to identify venous thromboembolism (VTE) events. Our objective was to assess the validity of using International Classification of Disease, 9th Revision (ICD-9) codes in identifying recurrent VTE. (Source: Thrombosis Research)
Source: Thrombosis Research - March 4, 2020 Category: Hematology Authors: Christine Baumgartner, Alan S. Go, Dongjie Fan, Sue Hee Sung, Daniel M. Witt, John R. Schmelzer, Marc S. Williams, Steven H. Yale, Jeffrey J. VanWormer, Margaret C. Fang Tags: Full Length Article Source Type: research

Incidence and risk factors of preoperative venous thromboembolism and pulmonary embolism in patients with ovarian cancer
To determine the incidence and predisposing factors of preoperative venous thromboembolism (VTE), especially pulmonary embolism (PE) in patients with ovarian cancer. (Source: Thrombosis Research)
Source: Thrombosis Research - March 3, 2020 Category: Hematology Authors: Shanhui Liang, Wei Tang, Shuang Ye, Libing Xiang, Xiaohua Wu, Huijuan Yang Tags: Full Length Article Source Type: research

Preoperative direct oral anticoagulants treatment and all-cause mortality in elderly patients with hip fracture: A retrospective cohort study
Hip fracture is common among the elderly and is associated with increased morbidity and mortality, particularly when surgery is delayed. Direct oral anticoagulants (DOACs) use might increase bleeding and postpone hip repair surgery. We aimed to assess the association between preoperative DOACs use and adverse outcomes in elderly patients with hip fracture. (Source: Thrombosis Research)
Source: Thrombosis Research - March 3, 2020 Category: Hematology Authors: Walid Saliba, Anat Arbel, Zomoroda Abu-Full, Shai Cohen, Gad Rennert, Meir Preis Tags: Full Length Article Source Type: research

“Wolverine, I think it's called: Blood thinners but in tablets.” Patients experience of living with cancer associated thrombosis in New Zealand (PELICANZ)
The long-term physical consequences of venous thromboembolism (VTE) have been recognized for some time, yet it is only recently that the psychological sequalae have garnered interest. Persistent anxiety commonly follows a thrombotic event irrespective of clot size, location or associated symptom burden [1,2]. Some patients may even experience symptoms similar to post-traumatic stress disorder, a condition termed “Post Thrombotic Panic Syndrome” [3]. The presence of malignancy provides an additional layer of psychological complexity to a VTE diagnosis since a cancer associated thrombosis (CAT) is perceived an ad...
Source: Thrombosis Research - March 2, 2020 Category: Hematology Authors: Tracey Woulfe, Kiri Mann, Daryl Pollack, Parinita Swarnkar, Annmarie Nelson, Simon Noble Tags: Letter to the Editors-in-Chief Source Type: research

Seventeen novel SERPINC1 variants causing hereditary antithrombin deficiency in a Czech population
Antithrombin (AT) as a serpin is a plasma inhibitor especially of thrombin and factor Xa [1]. AT deficiency (ATD) as an autosomal dominant disease is an important cause of inherited thrombophilia [2]. Its prevalence in the general population is estimated at 0.02% –0.2%; in individuals with venous thromboembolism (VTE), 1%–7%. Thus, the relative risk of a first VTE episode is increased 16-fold compared with the controls. It is the most substantial increase of VTE risk in comparison with other inherited thrombophilias, such as protein C and S deficiencies, factor 5 c.1601G > A and factor 2 c.*97G > ...
Source: Thrombosis Research - March 2, 2020 Category: Hematology Authors: Dana Provazn íková, Miloslava Matýšková, Irena Čápová, Dagmar Grančarová, Eva Drbohlavová, Marie Šlechtová, Ingrid Hrachovinová Tags: Letter to the Editors-in-Chief Source Type: research

Platelet and megakaryocyte CD40L expression in β-Thalassemic patients
β-Thalassemia is an inherited disease caused by a decrease or absence of β-globin chain synthesis and is often associated with inflammatory processes and hypercoagulation state [1,2]. It is largely accepted that platelets play a key role in inflammation and thrombosis and that CD40L is involved in both these processes; it is strongly expressed by platelets and is rapidly cleaved to generate a soluble form (sCD40L). Previous studies suggested that platelet-associated CD40L can be biochemically modulated during megakaryocyte (MK) differentiation [3,4]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 2, 2020 Category: Hematology Authors: Ornella Morsilli, Raffaella Guerriero, Valentina Lulli, Laura Maffei, Luca Pasquini, Fabio Maria Pulcinelli, Francesco Sorrentino, Marco Gabbianelli Tags: Letter to the Editors-in-Chief Source Type: research

Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults
Purified skeletal muscle myosin (SkM) binds factor Xa and is procoagulant. The molecular forms of SkM in human plasma have not been characterized. (Source: Thrombosis Research)
Source: Thrombosis Research - February 27, 2020 Category: Hematology Authors: Taichi K. Deguchi, Hiroshi Deguchi, Zihan Guo, Darlene J. Elias, John H. Griffin Tags: Full Length Article Source Type: research

Argatroban dosing requirements in extracorporeal life support and other critically ill populations
Argatroban is a parenteral direct thrombin inhibitor that requires close monitoring to ensure safety and efficacy. Limited data exist to describe its effect in critically ill patients. This was a retrospective, single-center, cohort study that aimed to compare argatroban dosing requirements in those receiving extracorporeal life support (ECLS), continuous renal replacement therapy (CRRT), or neither. Organ dysfunction was assessed using a modified version of the Sequential Organ Failure Assessment (modSOFA) that incorporated the use of extracorporeal support systems. (Source: Thrombosis Research)
Source: Thrombosis Research - February 27, 2020 Category: Hematology Authors: J. Spencer Dingman, Zachary R. Smith, Victor E. Coba, Michael A. Peters, Long To Tags: Full Length Article Source Type: research

Ex vivo effect of hemostatic therapy in subarachnoid and intracerebral hemorrhage
Rebleeding and hematoma growth are serious complications in subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH). As treatment options are sparse, a mechanistic approach may reveal new therapeutic targets. (Source: Thrombosis Research)
Source: Thrombosis Research - February 26, 2020 Category: Hematology Authors: Christine Lodberg Hvas, Signe Voigt Lauridsen, Emilie Sandgaard Pedersen, Tua Gyldenholm, Anne-Mette Hvas Tags: Full Length Article Source Type: research

Higher FVIII:C measured by chromogenic substrate assay than by one-stage assay is associated with silent hemophilic arthropathy
The Joint Outcome Study demonstrated that prophylactic therapy reduced joint bleeding and improved joint status. However, magnetic resonance imaging (MRI) revealed that the joints of patients who had no clinically evident joint bleeding (CEJB) displayed some abnormalities indicative of hemophilic arthropathy [1]. One explanation might be the presence of subclinical joint bleeding that passed unrecognized by patients. However, although many reports have implied their existence [1,2], such bleeds have remained unproven. (Source: Thrombosis Research)
Source: Thrombosis Research - February 22, 2020 Category: Hematology Authors: Mika Ogawa, Nobuaki Suzuki, Nobunori Takahashi, Shogo Tamura, Atsuo Suzuki, Sachiko Suzuki, Yuua Hattori, Misaki Kakihara, Takeshi Kanematsu, Toshihisa Kojima, Akira Katsumi, Fumihiko Hayakawa, Tetsuhito Kojima, Naoki Ishiguro, Hitoshi Kiyoi, Tadashi Mats Tags: Letter to the Editors-in-Chief Source Type: research

Editorial Board
(Source: Thrombosis Research)
Source: Thrombosis Research - February 21, 2020 Category: Hematology Source Type: research

Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation
Ischemic heart disease and stroke are major causes of death and morbidity worldwide. Coronary and cerebrovascular events are a consequence of thrombus formation caused by atherosclerotic plaque rupture or embolism, both of which result from platelet activation and aggregation and thrombin-mediated fibrin generation via the coagulation cascade [1]. In addition, thrombin is also one of the most effective platelet activators [2]. We focused on a novel thrombus formation mechanism called thrombin-mediated platelet stimulation and established thrombin-induced platelet aggregation [3]. (Source: Thrombosis Research)
Source: Thrombosis Research - February 21, 2020 Category: Hematology Authors: Keisuke Tsuda, Tatsunori Natori, Mie Shimizu, Yoko Ishigaku, Kiyotaka Oi, Shinsuke Narumi, Asami Kamada, Makiko Yoshida, Kazumasa Oura, Tetsuya Maeda, Yasuo Terayama Tags: Letter to the Editors-in-Chief Source Type: research

Physical activity and respiratory symptoms after pulmonary embolism. A longitudinal observational study
Acute pulmonary embolism (PE) is a major cause of hospitalization and morbidity. Common symptoms are dyspnea and respiratory. Physical activity (PA) and respiratory symptoms during the first year after PE are not previously studied. The aim of the study was to describe PA and respiratory symptoms, to have as base for recommendations on PA after PE. (Source: Thrombosis Research)
Source: Thrombosis Research - February 20, 2020 Category: Hematology Authors: Jenny Sofia Danielsbacka, Kaisa Mannerkorpi, Monika Fagevik Ols én Tags: Full Length Article Source Type: research

Treatment of venous thromboembolism in Northern Italy: A population-based study from 2013 to 2018
The standard of care for venous thromboembolism (VTE) includes initial treatment with heparin followed by vitamin K antagonists (VKAs) [1]. Over the past decade, non-vitamin K antagonists (NOACs) have been compared with initial low-molecular-weight heparin (LMWH) followed by long-term VKA treatment; they have proved non-inferior for recurrent VTE, with a lower risk of major bleeding [2]. NOACs are recommended by the 2016 American College of Chest Physicians and 2017 European Society of Cardiology guidelines for deep venous thrombosis (DVT) and pulmonary embolism (PE). (Source: Thrombosis Research)
Source: Thrombosis Research - February 20, 2020 Category: Hematology Authors: Marta Baviera, Luca Barcella, Tommaso Vannini, Pierluca Colacioppo, Irene Marzona, Mauro Tettamanti, Luca Merlino, Ida Fortino, Enrica Morra, Anna Falanga, Maria Carla Roncaglioni Tags: Letter to the Editors-in-Chief Source Type: research

Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: Meta-analyses of incidence, temporal trends and potential risk factors
There is wide variability in reported venous thromboembolism (VTE) incidence following total shoulder replacement (TSR) or total elbow replacement (TER). It is uncertain which risk factors influence the risk of VTE following TSR or TER. We conducted a PRISMA compliant meta-analysis to evaluate the incidence, temporal trends and potential risk factors for VTE following primary TSR and TER. (Source: Thrombosis Research)
Source: Thrombosis Research - February 20, 2020 Category: Hematology Authors: Setor K. Kunutsor, Matthew C. Barrett, Michael R. Whitehouse, Ashley W. Blom Tags: Full Length Article Source Type: research

Do asymptomatic clots in children matter?
Asymptomatic venous thrombosis is a common complication among hospitalised paediatric patients. Previous guidelines recommend the treatment of all asymptomatic venous thrombosis, even when the diagnosis is made incidentally or the risk factor is no longer present. Whether clinicians need to treat all asymptomatic thrombosis in children, given the likelihood of long-term sequelae, is unclear and there are significant risks associated with anticoagulation treatment. Asymptomatic thrombosis in children is most frequently associated with central venous catheters (CVCs). (Source: Thrombosis Research)
Source: Thrombosis Research - February 18, 2020 Category: Hematology Authors: Sophie Jones, Paul Monagle, Fiona Newall Tags: Review Article Source Type: research

Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia – time to reconsider current approaches?
Acute Lymphoblastic Leukemia (ALL) is the commonest malignancy in childhood with a second incidence peak in adulthood. Improvements in pediatric therapy including the addition of L-asparaginase (L-ASP) have enabled cure rates in excess of 90% to be achieved in children. More recently L-ASP-containing pediatric protocols are being used to treat younger adults with ALL and have improved survival by approximately 2-fold. However, a toxicity associated with L-ASP-containing therapy in ALL is venous thromboembolism (VTE) which is associated with significant morbidity in this patient population and results in interruptions in L-...
Source: Thrombosis Research - February 18, 2020 Category: Hematology Authors: J. Fulcher, M. Carrier Tags: Short Review Source Type: research

Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review
The value of D-dimer testing for the diagnosis of thrombosis in unusual sites is not properly established and evidence is scarce. We performed a systematic review of the literature. (Source: Thrombosis Research)
Source: Thrombosis Research - February 15, 2020 Category: Hematology Authors: L. Ordieres-Ortega, P. Demelo-Rodr íguez, F. Galeano-Valle, B.M.M. Kremers, A.J. ten Cate-Hoek, H. ten Cate Tags: Short Review Source Type: research

Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP
Long-acting recombinant factor IX (FIX) products may simplify the surgical treatment of haemophilia B patients. The impact of rIX-FP, a recombinant FIX fused to recombinant albumin, on FIX consumption and surgical management was assessed in patients with haemophilia B. (Source: Thrombosis Research)
Source: Thrombosis Research - February 14, 2020 Category: Hematology Authors: Julie Curtin, Elena Santagostino, Faraizah Abdul Karim, Yanyan Li, Wilfried Seifert, Claude N égrier Tags: Full Length Article Source Type: research

Patient characteristics and long –term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism
Little is known about the clinical course and treatment decisions in patients with cancer-associated venous thromboembolism (VTE) beyond the initial treatment period of 3 to 6  months. This information is important for clinicians and patients to inform their decisions regarding duration of anticoagulation. (Source: Thrombosis Research)
Source: Thrombosis Research - February 13, 2020 Category: Hematology Authors: Robert A. Schmidt, Alaa Al Zaki, Nikolas Desilet, Elena Szefer, Namali Ratnaweera, Erica Peterson, Agnes Y.Y. Lee Tags: Full Length Article Source Type: research

Patient characteristics and long –term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism
Little is known about the clinical course and treatment decisions in patients with cancer-associated venous thromboembolism (VTE) beyond the initial treatment period of 3 to 6  months. This information is important for clinicians and patients to inform their decisions regarding duration of anticoagulation. (Source: Thrombosis Research)
Source: Thrombosis Research - February 13, 2020 Category: Hematology Authors: Robert Schmidt, Alaa Al Zaki, Nikolas Desilet, Elena Szefer, Namali Ratnaweera, Erica Peterson, Agnes Y.Y. Lee Tags: Full Length Article Source Type: research

Thrombin dynamics in children with liver disease or extrahepatic portal vein obstruction or shunt
This study aims to characterise the mechanism of thrombin generation in this population, focusing on prothrombin conversion and thrombin inhibition. (Source: Thrombosis Research)
Source: Thrombosis Research - February 13, 2020 Category: Hematology Authors: William Beattie, Romy Kremers, Maria Magnusson, Tessa Peters, Bas de Laat, Winita Hardikar, Paul Monagle, Vera Ignjatovic Tags: Full Length Article Source Type: research

Cellular effects of factor VII activating protease (FSAP)
Factor VII activating protease (FSAP) is a circulating serine protease of broad specificity that is likely to be involved in many pathophysiological processes. The activation of the circulating zymogen form of FSAP by histones, released from damaged cells, underlines its roles in regulating host responses to tissue damage and inflammation. Some of the direct cellular effects of FSAP are mediated through protease-activated receptors (PARs). Knock-down of each one of the four PARs in endothelial cells indicated that PAR-1 and -3 are involved in regulating endothelial permeability in response to FSAP. (Source: Thrombosis Research)
Source: Thrombosis Research - February 13, 2020 Category: Hematology Authors: Kristina Byskov, Michael Etscheid, Sandip M. Kanse Tags: Review Article Source Type: research

Non-vitamin K oral anticoagulants at the time of cardiac rhythm device surgery: A systematic review and meta-analysis
Use of non-vitamin K oral anticoagulants (NOACs) has rapidly increased worldwide. We aimed to systematically assess the available evidence regarding the safety and efficacy of NOACs in patients undergoing cardiac implantable electronic device (CIED) surgery. (Source: Thrombosis Research)
Source: Thrombosis Research - February 12, 2020 Category: Hematology Authors: Antonio Creta, Malcolm Finlay, Ross J. Hunter, Anthony Chow, Simon Sporton, Amal Muthumala, Gurpreet Dhillon, Nikolaos Papageorgiou, Peter Waddingham, Syed Ahsan, Mehul Dhinoja, Mark J. Earley, Fakhar Khan, Martin Lowe, Mahmood Ahmad, Danilo Ricciardi, Fr Tags: Review Article Source Type: research

A comparison of the effects of the lipid-soluble CORM-2 and the water-soluble CORM-3 and CORM-A1 on platelet adhesion: The role of arachidonic acid metabolism
Gasomediators, such as nitric oxide, carbon monoxide (CO) and hydrogen sulfide, exert a range of effects on various elements of hemostasis, including the action of blood platelets. CO is known to be produced endogenously, and may provide beneficial effects when present at lower concentrations. In a typical human body, approximately 500 μmoles of CO is generated per day, at a rate of 20 μmoles/h [1]. However, as it is difficult to translocate CO through the organism, CO-releasing molecules (CORMs) are of considerable interest as potential transporters in therapy. (Source: Thrombosis Research)
Source: Thrombosis Research - February 11, 2020 Category: Hematology Authors: Weronika Adach, Beata Olas Tags: Letter to the Editors-in-Chief Source Type: research

Evaluation of anti-Xa activity after injection of a heparin lock for dialysis catheters in intensive care: A prospective observational study
Acute kidney injury (AKI) is a serious and frequent complication in the intensive care unit (ICU) [1] and can require the initiation of renal replacement therapy (RRT). Venous catheters are currently the preferred vascular access route for patients with AKI who require RRT [2,3], but there is a risk of catheter infection or thrombosis. To prevent these complications, lock solutions are instilled into the lumen of the hemodialysis catheter after each session and left in place until the next use. Sodium citrate and heparin locks are widely used. (Source: Thrombosis Research)
Source: Thrombosis Research - February 11, 2020 Category: Hematology Authors: Julien Bovet, Agn ès Soudry-Faure, Hamid Merdji, Eléa Ksiazek, Jean-Pierre Quenot, Ferhat Meziani, Amélie Cransac, Julie Helms Tags: Letter to the Editors-in-Chief Source Type: research

Nocturnal light exposure stimulates the cardiac fibrinolysis system and stress responses in C3H/He mice
Plasminogen activator inhibito-1 (PAI-1) is a primary physiological inhibitor of tissue plasminogen activator (tPA) and the major inhibitor of fibrinolysis [1]. Tissue factor (TF) plays a crucial role at the beginning of the coagulation pathway in initiating the formation of a thrombus and blood coagulation, and is prothrombotic [1]. The serine protease, tPA activates plasmin, a promoter of fibrin degradation. Elevated circulating PAI-1 levels are associated with an increased risk of myocardial infarction, and PAI-1 has been suggested to be the protein most involved in regulating the fibrinolytic system [2]. (Source: Thrombosis Research)
Source: Thrombosis Research - February 5, 2020 Category: Hematology Authors: Michiko T. Yasuda, Yuto Watanabe, Takashi Hosono, Taiichiro Seki, Taka-aki Suzuki, Hiroyuki Sakakibara, Kayoko Shimoi Tags: Letter to the Editors-in-Chief Source Type: research